Anzeige
Mehr »
Login
Sonntag, 13.06.2021 Börsentäglich über 12.000 News von 662 internationalen Medien
Angehender Nickelproduzent mit 439 Mio. $ Gewinn pro Jahr!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P2NP ISIN: US83548R1059 Ticker-Symbol: H3D 
Tradegate
11.06.21
19:38 Uhr
1,336 Euro
+0,025
+1,91 %
1-Jahres-Chart
SONNET BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2561,39611.06.

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report2
DiSonnet Bio issued U.S. patent for its albumin binding technology3
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
DiSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology282U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion ProteinsPRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics...
► Artikel lesen
17.05.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report2
17.05.Sonnet BioTherapeutics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
17.05.Sonnet BioTherapeutics Holdings, Inc. - 10-Q, Quaterly Report-
17.05.Sonnet BioTherapeutics reports FQ2 results2
17.05.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update241SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE...
► Artikel lesen
10.05.Sonnet Bio's Interleukin 12 Candidate For Solid Tumor Shows Encouraging Action Preclinical Studies4
10.05.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)294The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome. Pharmacokinetic...
► Artikel lesen
03.05.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report-
03.05.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics354New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories Upfront and potential milestone payments totaling up to $21 Million with up to...
► Artikel lesen
30.03.Sonnet Biotherapeutics provides 2021 business update3
30.03.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
29.03.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides 2021 Business Update429PRINCETON, NJ / ACCESSWIRE / March 29, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs...
► Artikel lesen
22.03.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations337PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs...
► Artikel lesen
16.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report6
16.02.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update674SONN-1010, fully human IL-12 configured using FHAB platform, Non-Human Primate study informs pharmacokinetic profile Launch of At-The-Market Offering Program for up to $15,875,000 of common stock PRINCETON...
► Artikel lesen
16.02.Sonnet BioTherapeutics Holdings, Inc. - 10-Q, Quaterly Report5
05.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report11
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1